Abstract : The present study sought to compare the effectiveness of a proton pump inhibitor PPI with that of a histamine H 2 receptor antagonist H2RA for treating functional dyspepsia FD in a real-world setting. A multicenter, open-label, randomized trial was conducted. FD patients were randomly assigned to receive either 20 mg, q.d., omeprazole OPZ ; a PPI or 150 mg, b.i.d., ranitidine hydrochloride RAN ; an H2RA for 4 weeks. Any change in the total Gastrointestinal Symptom Rating Scale GSRS score delta at week 4 was the primary outcome measure. Secondary outcome measures were reductions in scores for individual items on the GSRS at week 4. As a subanalysis, patients were strati ed according to Helicobacter pylori serology and the analyses were repeated. The mean SD deltas in total GSRS score for the OPZ and RAN groups were 0.8 0.7 and 0.6 0.6, respectively P 0.098 ; however, the delta in re ux score between the OPZ and RAN groups differed signi cantly 1.1 0.7 vs. 0.5 0.5, respectively ; P 0.001 . There were no significant differences between the two groups in any other scores for individual items on the GSRS. The results of the subanalysis were like those of the main analysis. The PPI and H2RA produced a comparable improvement in symptoms of FD in our patient cohort, thus we propose no advantage would be gained in using a PPI rather than an H2RA.
et al 3 reported that 6.6 of patients presenting for the rst time at a hospital department of general medicine complained of dyspeptic symptoms 3 .
Dyspeptic symptoms can be a sign of structural diseases, such as peptic ulcer or cancer, although recent cross-sectional studies reported that less than 10 of dyspeptic patients showed macroscopic disease 4 5 . Thus, in most patients, dyspeptic symptoms are functional , and this subgroup of patients is referred to as having functional dyspepsia FD 6 .
The pathophysiology underlying FD symptoms remains elusive, with many factors including gastric motor function, gastric acid, visceral perception, and psychosocial factors implicated in generating typical FD 7 8 . Of these, gastric acid is a well-known irritant that could promote upper abdominal symptoms. Although gastric acid constitutively resides in the stomach, Oshima et al 9 demonstrated that intragastric perfusion of 0.1 M hydrochloric acid induced a variety of symptoms, including epigastric pain, nausea, bloating, and satiety, particularly in FD subjects. Moreover, Ishii et al 10 demonstrated that the duodenum of FD patients was more susceptible to acid than that of healthy volunteers. These data thus suggest gastric acid as a potent therapeutic target in patients with FD symptoms. Acid-suppressive agents, namely histamine H 2 receptor antagonists H2RAs and proton pump inhibitors PPIs , have been used historically to treat patients with FD symptoms [11] [12] [13] . Both types of medication have clinical bene t in improving symptoms, although it is reasonable to assume that PPIs could be more effective than H2RAs considering that the former shows more potent acid-suppressive effects. This assumption has been supported by randomized controlled trials that showed higher ef cacy of PPIs over H2RAs for the management of FD [14] [15] [16] . However, these studies were conducted in Western countries, and direct comparative studies between PPIs and H2RAs in Japanese patients are scarce. Thus, the the present study aimed to compare the effectiveness of a PPI with that of an H2RA in Japanese patient presenting with symptoms of FD.
Materials and methods

Study population
From 2006 to 2008, patients between 20 and 80 years of age who were suffering from upper abdominal symptoms were asked to participate in the study. At the initial visit, subjects were interviewed to assess which speci c symptom was the predominant, as determined by the attending physician. Because the present study sought to re ect real-world practice, there were no limits imposed on the duration and severity of symptoms when recruiting subjects ; however, patients were excluded from the study if they met any of the following criteria : predominant symptom of heartburn ; symptoms suggestive of irritable bowel syndrome ; comorbid organ failure e.g., heart, liver, and kidney ; on medications that affect gastric acid and upper gastrointestinal symptoms, including non-steroidal anti-in ammatory drugs NSAIDs , corticosteroids, and antidepressants ; suspected malignant disease ; history of gastric surgery ; pregnant or lactating ; and, alcohol abuse.
Study design
The present study was a multicenter, open-label, randomized trial.
Setting
One tertiary care center and six primary care of ces participated in the present study.
Study protocol
Patients underwent esophagogastroduodenoscopy and blood tests to exclude any organic and/ or metabolic diseases. Helicobacter pylori HP infection was determined by serology. The Gastrointestinal Symptom Rating Scale GSRS was used to score upper abdominal symptoms, because this questionnaire has been widely used in many clinical trials and has already been validated 17 . 18 . Subjects were allocated to the different groups using a computer-generated randomization list strati ed by each institution. Subjects were asked to return on weeks 2 and 4 to complete the GSRS again at both time points. During the study period, patients were not permitted to take medicines that could potentially affect gastric acid and upper abdominal symptoms, such as antacids, prokinetics, NSAIDs, and antidepressants.
Outcome measures and statistical analyses
The primary outcome measure for both groups was the reduction delta in total GSRS score from all 15 questions at week 4. Secondary outcome measures were reductions in scores for individual items on the GSRS at week 4. Because HP infection affects the action of gastric acid suppressants and provokes upper abdominal symptoms 19 20 , patients were also strati ed according to HP serology, and the primary and secondary outcome measures were further examined. Nine patients were lost to follow-up at week 4 and missing data were accounted for using the last observation i.e., at week 2 and a carried forward method. Patient demographics were analyzed using descriptive statistics. For comparisons of numerical and categorical data, the Mann-Whitney U-test and Fischer s exact probability test were used respectively, as appropriate. To examine the significance of differences between groups in primary and secondary outcome measures, t-tests were used. All tests were two sided and P 0.05 was considered signi cant. Analysis was based on the full data set. Statistical analyses were performed using JMP Pro 10.0.2 SAS Institute Inc., Cary, NC, USA . Unless indicated otherwise, data are presented as the mean SD.
Ethical considerations
The study protocol was approved by the local ethics committees of the participating institutions Ethics Committee of Showa University School of Medicine, No 447 . All participants provided written informed consent. Table 1 During the study period, 79 patients were recruited to the present study : 40 were from the primary care medical offices and 39 were from the tertiary care center. Mean patient age was 52 15 years, and there were more female than male patients 59 75
Results
Demographics
vs. 20 25 , respectively . Approximately one-fth of patients in both the OPZ and RAN groups were HP seropositive. In terms of the duration of dyspeptic symptoms, symptoms had been present for 6 months in 37 patients 50 , 3-6 months in 5 patients 4 , 1-3 months in 12 patients 10 , and for 1 month in 5 patients 5 . There were no signi cant differences in age, sex, duration of symptoms, and HP seropositivity between the OPZ and RAN groups. At baseline, there was no signi cant difference in the total GSRS score between the OPZ and RAN groups 2.4 0.7 and 2.5 0.9, respectively ; P 0.534 .
Primary outcome measure Table 2
We assigned 41 and 38 patients to the OPZ and RAN groups, respectively. At week 4, although delta for the total GSRS score was greater in the OPZ than the RAN group 0.8 0.7 vs. 0.6 0.6, respectively , the difference did not reach statistical signi cance P 0.098 .
Secondary outcome measures
Secondary outcome measures were changes in scores delta for individual items on the GSRS relating to upper abdominal symptoms, including re ux, abdominal pain, and indigestion Table 2 . At week 4, the GSRS re ux score delta was signi cantly greater in the OPZ than the RAN group 1.14 0.7 vs. 0.5 0.5, respectively ; P 0.001 ; however, there were no signi cant differences between the OPZ and RAN groups in the deltas for abdominal pain score 1.0 0.8 vs. 0.9 0.1, respectively ; P 0.6 or indigestion score 1.0 0.9 and 0.6 0.9, respectively ; P 0.14 .
Subanalyses Tables 3, 4
The number of HP-seropositive patients was too small for statistically signi cant subanalyses, only data from the seronegative patients were used in the nal subanalyses Table 3 , with 28 and 25 patients assigned to the OPZ group and RAN group, respectively. As indicated in Table 4 , the Table 2 . Reduction in Gastrointestinal Symptom Rating Scale GSRS scores total and for individual items on the GSRS at week 4 in patients allocated to the omeprazole or ranitidine hydrochloride treatment groups results of subanalyses were consistent with those of the main analyses, with no signi cant difference in the delta for the total GSRS score between the OPZ and RAN groups 0.8 0.7 vs. 0.5 0.6, respectively ; P 0.131 or in the abdominal pain and indigestion scores individually P 0.876 and P 0.110, respectively , whereas there was a statistically signi cant difference between the two groups in the re ux score.
Discussion
With no evidence of structural disease, the speci c symptoms of FD were the major targets of treatment in the present study. Symptom improvement, as measured by the total GSRS score, was comparable between the two groups ; however, comparing individual symptom scores on the GSRS revealed a signi cantly greater reduction in re ux score for the OPZ group compared to the RNA patients, with no signi cant differences between the two groups for any of the other individual symptom scores. Based on these results, we found no clear bene t in using a PPI for the treatment of FD symptoms in place of an H2RA.
This study was not designed to investigate the effect of gastric acid inhibition on FD symptoms because a placebo arm was not included. Nevertheless, there were signi cant decreases in the total GSRS score, as well as in the individual re ux, abdominal pain, and indigestion scores, in both groups at week 4 compared with week 0 data not shown , indicating that gastric acid inhibition certainly helps improve dyspeptic symptoms. Considering that PPIs more potently inhibit gastric acid secretion than H2RAs, the superiority of PPIs in improving dyspeptic symptoms was anticipated ; however, we found no such differences in the present study groups. One possible explanation is that, as mentioned earlier, the mechanisms responsible for the generation of FD symptoms are multifactorial, and FD might not be a primarily gastric acid-related condition. Based on that proposal, gastric acid inhibition by the H2RA might have been suf cient to improve the symptoms. Indeed, Japanese clinical practice guidelines for FD do not mention which agent should be used as rst-line therapy 21 .
The results of the present study are not in agreement with previous randomized controlled trials in Western populations that showed superior effectiveness of PPIs over H2RAs in the management of FD [14] [15] [16] . There are several reasons for the apparent discrepancy. First, in the present study we did not place any limits on symptom severity when considering patients for inclusion, whereas previous studies recruited sicker patients with moderate to severe symptoms at the time of treatment [14] [15] [16] . The milder the initial symptoms are, the more dif cult it is to recognize therapeutic gain. Second, there are differences between previous studies in the methods used to assess symptoms following intervention. In the present study we used the GSRS and compared reductions delta in scores between the groups, whereas previous studies used different questionnaires, such as the Global Overall Severity GOS score 16 , or physicians assessments of symptoms 14 . Furthermore, in contrast to the present study, the outcome measure in previous studies was the proportion of patients who achieved complete and/or substantial symptomatic resolution [14] [15] [16] . Third, there are differences in inclusion criteria between studies, and therefore the study populations. For example, Jones and Baxter 14 recruited either re ux-like or ulcer-like dyspeptic patients, but not those with dysmotility-like disease, whereas the patients in the study of Mason et al 15 had bene ted from antacid prior to being recruited to the study. Thus, both these former study populations would have been susceptible to acid-suppressive agents, which may differ from the present study population. Finally, dyspepsia in Western patients could be more acid related than in Japanese patients. For example, Mahadeva et al 22 reported that the prevalence of gastroesophageal re ux disease GERD among dyspeptic patients is more common in British than South-East Asian subjects. Taking these factors into consideration, it is not reasonable to compare the present study with previous reports.
Comparing scores for individual items on the GSRS, we found that the PPI significantly reduced the re ux score relative to the H2RA, although the two agents were comparable for the other individual score items tested. Although patients who had predominantly re ux-associated symptoms at the time of recruitment were excluded from the present study, it has been shown recently that a substantial number of patients with FD also have GERD 23 . Given that the therapeutic bene t of PPIs for GERD is de nitely greater than that of H2RAs 24 , the ndings of the present study are quite reasonable. Indeed, Carlsson et al 25 demonstrated significant symptom relief with the use of PPIs in FD patients who were prespecified to have refluxpredominant symptoms. Considering the high prevalence of overlapping FD and GERD, the choice of a PPI as rst-line therapy could be justi ed in a subgroup of dyspeptic patients with concomitant GERD symptoms. The reductions in symptom scores for abdominal pain and indigestion, two major symptoms in FD, were comparable between the OPZ and RAN groups in the present study. Historically, gastric acid and delayed gastric emptying have been therapeutic targets for abdominal pain and indigestion, respectively, prompting the use of gastric acid suppressants and prokinetics 26 . Consistent with these observations, Matsueda et al 27 reported that the novel prokinetic, acotiamide, was effective in FD patients who fulfilled the Rome diagnostic criteria for postprandial distress syndrome ; however, recent studies demonstrated that specific dyspeptic symptoms do not re ect the underlying pathological mechanism 28 29 . In addition, we did not prespecify the presence of dyspeptic symptoms in the inclusion criteria because of our aim to compare the effectiveness of the PPI and H2RA in a real-world setting. Such patient heterogeneity could have resulted in the lack of difference between the PPI and H2RA in the present study. Because HP infection has a considerable effect on upper gastrointestinal physiology, it is conceivable that HP status affects the pharmacological properties of PPIs and H2RAs. Although Blum et al reported that a therapeutic benefit of PPIs for FD was observed in HP-positive patients 30 , the CADHET study, which recruited HP-negative patients, also demonstrated the superiority of PPIs over H2RA in FD 16 . In the present study, the results in HP-negative patients were similar to those in the total patient group, indicating that HP infection is less likely to affect the short-term effect of gastric acid suppressants on dyspeptic symptoms. The frequency of HP-positive patients in the present study was 13 , similar to that previously reported in the Japanese population 31 , so that our ndings may be generalizable to the Japanese population. However, because of the small sample size of the present study, larger studies are needed to con rm our ndings. The present study has several limitations. First and most importantly, the present study lacks statistical power. At the time of study design, we could not nd any large-scale studies assessing the effectiveness of PPIs or H2RAs on FD in the Japanese population, so that estimating the number of patients needed to provide power in present study was dif cult. Second, other potent confounders, including comorbidities, particularly psychiatric diseases, family history, and drug compliance, were not included in the analyses. Third, this was an open-label study, and thus could have affected patients perceptions. Nonetheless, the present study is the rst reported to directly he effectiveness of a PPI and an H2RA in Japanese FD patient, and the study population appears to be representative of patients in daily clinical practice.
In conclusion, PPI and H2RA produced comparable improvements in FD symptoms in our study cohort. There was seemingly no advantage in using the PPI over the H2RA ; however, a subgroup of dyspeptic patients who also have GERD might bene t more from a PPI.
